Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Inhaled FB2001 in Mild to Moderate COVID-19
NCT05675072Phase 3Unknown
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing FB2001 Group with Placebo Group (2 arms). Primary endpoint: Time to sustained recovery of COVID-19-related signs/symptoms. Status: unknown.
02
Drugs
Compound 7b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05675072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675072.